Joint Purification Systems, an early-stage medical device company, reported a $7.8 million Series A financing round.
Here are five things to know.
1. Joint Purification Systems develops combination products for chronic peri-prosthetic joint infection treatment.
2. Johnson & Johnson Innovation – JJDC led the financing, and MedVest Fund II was a new investor in the round.
3. Joint Purification Systems will use the funding to prepare its X7 Spacer System for human clinical studies.
4. The JPS X7 Spacer System features a patented temporary orthopedic spacer with locally delivered antibiotics. The FDA granted the antibiotics Orphan Drug Designation in January 2017.
5. Joint Purification Systems is privately held and located in Solana Beach, Calif.